Tumor Cell Dissemination: Emerging Biological Insights from Animal Models and Cancer Patients

Cancer Cell

Volumn 23, Issue 5, 2013, Pages 573-581

  Kang, Yibin ^a   Pantel, Klaus ^b  

^a PRINCETON UNIVERSITY   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALGRANULIN A; CALGRANULIN B; CXCL1 CHEMOKINE; FASCIN; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MICRORNA 200; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; RANTES; TRANSCRIPTION FACTOR FOXC2; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 1; WNT2 PROTEIN;

BREAST CANCER; CANCER PATIENT; CELL ADHESION; CIRCULATING TUMOR CELL; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NONHUMAN; PANCREAS CANCER; PLASTICITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION;

EID: 84877816994     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.04.017     Document Type: Review

References (100)

1. Acharyya S., Oskarsson T., Vanharanta S., Malladi S., Kim J., Morris P.G., Manova-Todorova K., Leversha M., Hogg N., Seshan V.E., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150:165-178.
2. Algra A.M., Rothwell P.M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012, 13:518-527.
3. Alix-Panabières C., Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin. Chem. 2013, 59:110-118.
4. Alix-Panabières C., Schwarzenbach H., Pantel K. Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 2012, 63:199-215.
5. Armstrong A.J., Marengo M.S., Oltean S., Kemeny G., Bitting R.L., Turnbull J.D., Herold C.I., Marcom P.K., George D.J., Garcia-Blanco M.A. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 2011, 9:997-1007.
6. Bednarz N., Eltze E., Semjonow A., Rink M., Andreas A., Mulder L., Hannemann J., Fisch M., Pantel K., Weier H.U., et al. BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin. Cancer Res. 2010, 16:3340-3348.
7. Bednarz-Knoll N., Alix-Panabières C., Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012, 31:673-687.
8. Bidard F.C., Fehm T., Ignatiadis M., Smerage J.B., Alix-Panabières C., Janni W., Messina C., Paoletti C., Müller V., Hayes D.F., et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2012, Published online November 6, 2012. 10.1007/s10555-012-9398-0.
9. Bidwell B.N., Slaney C.Y., Withana N.P., Forster S., Cao Y., Loi S., Andrews D., Mikeska T., Mangan N.E., Samarajiwa S.A., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 2012, Published online July 22, 2012. 10.1038/nm.2830.
10. Brabletz T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 2012, 12:425-436.
11. Brabletz S., Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer?. EMBO Rep. 2010, 11:670-677.
12. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., Knuechel R., Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 2001, 98:10356-10361.
13. Braun S., Kentenich C., Janni W., Hepp F., de Waal J., Willgeroth F., Sommer H., Pantel K. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J.Clin. Oncol. 2000, 18:80-86.
14. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N.Engl. J. Med. 2005, 353:793-802.
15. Cameron M.D., Schmidt E.E., Kerkvliet N., Nadkarni K.V., Morris V.L., Groom A.C., Chambers A.F., MacDonald I.C. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 2000, 60:2541-2546.
16. Campbell J.P., Karolak M.R., Ma Y., Perrien D.S., Masood-Campbell S.K., Penner N.L., Munoz S.A., Zijlstra A., Yang X., Sterling J.A., Elefteriou F. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 2012, 10:e1001363.
17. Celià-Terrassa T., Meca-Cortés O., Mateo F., de Paz A.M., Rubio N., Arnal-Estapé A., Ell B.J., Bermudo R., Díaz A., Guerra-Rebollo M., et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J.Clin. Invest. 2012, 122:1849-1868.
18. Chaffer C.L., Brennan J.P., Slavin J.L., Blick T., Thompson E.W., Williams E.D. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006, 66:11271-11278.
19. Chakrabarti R., Hwang J., Andres Blanco M., Wei Y., LukačiŠin M., Romano R.A., Smalley K., Liu S., Yang Q., Ibrahim T., et al. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat. Cell Biol. 2012, 14:1212-1222.
20. Chen Q., Zhang X.H., Massagué J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 2011, 20:538-549.
21. Chen D., Sun Y., Wei Y., Zhang P., Rezaeian A.H., Teruya-Feldstein J., Gupta S., Liang H., Lin H.K., Hung M.C., Ma L. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat. Med. 2012, 18:1511-1517.
22. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., Clouthier S.G., Wicha M.S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. USA 2012, 109:2784-2789.
23. Cooke V.G., LeBleu V.S., Keskin D., Khan Z., O'Connell J.T., Teng Y., Duncan M.B., Xie L., Maeda G., Vong S., et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012, 21:66-81.
24. Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., Inui M., Montagner M., Parenti A.R., Poletti A., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147:759-772.
25. De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13:97-110.
26. Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E., Peeper D.S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430:1034-1039.
27. Dunn L.K., Mohammad K.S., Fournier P.G., McKenna C.R., Davis H.W., Niewolna M., Peng X.H., Chirgwin J.M., Guise T.A. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 2009, 4:e6896.
28. Eckert M.A., Lwin T.M., Chang A.T., Kim J., Danis E., Ohno-Machado L., Yang J. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011, 19:372-386.
29. Erler J.T., Bennewith K.L., Nicolau M., Dornhöfer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
30. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., Le Q.T., Giaccia A.J. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
31. Francia G., Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 2011, 11:135-141.
32. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
33. Gao D., Joshi N., Choi H., Ryu S., Hahn M., Catena R., Sadik H., Argani P., Wagner P., Vahdat L.T., et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012, 72:1384-1394.
34. Gao H., Chakraborty G., Lee-Lim A.P., Mo Q., Decker M., Vonica A., Shen R., Brogi E., Brivanlou A.H., Giancotti F.G. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012, 150:764-779.
35. Giannoni E., Bianchini F., Calorini L., Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid. Redox Signal 2011, 14:2361-2371.
36. Gil-Bernabé A.M., Ferjancic S., Tlalka M., Zhao L., Allen P.D., Im J.H., Watson K., Hill S.A., Amirkhosravi A., Francis J.L., et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012, 119:3164-3175.
37. Grabinski N., Bartkowiak K., Grupp K., Brandt B., Pantel K., Jücker M. Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell. Signal. 2011, 23:1952-1960.
38. Gradilone A., Raimondi C., Nicolazzo C., Petracca A., Gandini O., Vincenzi B., Naso G., Aglianò A.M., Cortesi E., Gazzaniga P. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J.Cell. Mol. Med. 2011, 15:1066-1070.
39. Gumireddy K., Li A., Gimotty P.A., Klein-Szanto A.J., Showe L.C., Katsaros D., Coukos G., Zhang L., Huang Q. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat. Cell Biol. 2009, 11:1297-1304.
40. Guo W., Keckesova Z., Donaher J.L., Shibue T., Tischler V., Reinhardt F., Itzkovitz S., Noske A., Zürrer-Härdi U., Bell G., et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012, 148:1015-1028.
41. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8:1369-1375.
42. Hiratsuka S., Watanabe A., Sakurai Y., Akashi-Takamura S., Ishibashi S., Miyake K., Shibuya M., Akira S., Aburatani H., Maru Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008, 10:1349-1355.
43. Hou J.M., Krebs M.G., Lancashire L., Sloane R., Backen A., Swain R.K., Priest L.J., Greystoke A., Zhou C., Morris K., et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J.Clin. Oncol. 2012, 30:525-532.
44. Hüsemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., Forni G., Eils R., Fehm T., Riethmüller G., Klein C.A. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
45. Janni W., Vogl F.D., Wiedswang G., Synnestvedt M., Fehm T., Jückstock J., Borgen E., Rack B., Braun S., Sommer H., et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a European pooled analysis. Clin. Cancer Res. 2011, 17:2967-2976.
46. Joosse S.A., Hannemann J., Spötter J., Bauche A., Andreas A., Müller V., Pantel K. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin. Cancer Res. 2012, 18:993-1003.
47. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
48. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
49. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., Massagué J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
50. Kim N.H., Kim H.S., Li X.Y., Lee I., Choi H.S., Kang S.E., Cha S.Y., Ryu J.K., Yoon D., Fearon E.R., et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J.Cell Biol. 2011, 195:417-433.
51. Kim R.S., Avivar-Valderas A., Estrada Y., Bragado P., Sosa M.S., Aguirre-Ghiso J.A., Segall J.E. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS ONE 2012, 7:e35569.
52. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9:302-312.
53. Korpal M., Ell B.J., Buffa F.M., Ibrahim T., Blanco M.A., Celià-Terrassa T., Mercatali L., Khan Z., Goodarzi H., Hua Y., et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 2011, 17:1101-1108.
54. Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20:576-590.
55. Laffin B., Wellberg E., Kwak H.I., Burghardt R.C., Metz R.P., Gustafson T., Schedin P., Porter W.W. Loss of singleminded-2s in the mouse mammary gland induces an epithelial-mesenchymal transition associated with up-regulation of slug and matrix metalloprotease 2. Mol. Cell. Biol. 2008, 28:1936-1946.
56. Ledford H. Cancer theory faces doubts. Nature 2011, 472:273.
57. Lin K.Y., Lu D., Hung C.F., Peng S., Huang L., Jie C., Murillo F., Rowley J., Tsai Y.C., He L., et al. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res. 2007, 67:1832-1841.
58. López-Novoa J.M., Nieto M.A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 2009, 1:303-314.
59. Lu X., Yan C.H., Yuan M., Wei Y., Hu G., Kang Y. Invivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res. 2010, 70:3905-3914.
60. Lu X., Mu E., Wei Y., Riethdorf S., Yang Q., Yuan M., Yan J., Hua Y., Tiede B.J., Lu X., et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 2011, 20:701-714.
61. Malanchi I., Santamaria-Martínez A., Susanto E., Peng H., Lehr H.A., Delaloye J.F., Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
62. Mani S.A., Yang J., Brooks M., Schwaninger G., Zhou A., Miura N., Kutok J.L., Hartwell K., Richardson A.L., Weinberg R.A. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. USA 2007, 104:10069-10074.
63. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
64. Mego M., Mani S.A., Lee B.N., Li C., Evans K.W., Cohen E.N., Gao H., Jackson S.A., Giordano A., Hortobagyi G.N., et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int. J. Cancer 2012, 130:808-816.
65. Mejlvang J., Kriajevska M., Vandewalle C., Chernova T., Sayan A.E., Berx G., Mellon J.K., Tulchinsky E. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol. Biol. Cell 2007, 18:4615-4624.
66. Moody S.E., Perez D., Pan T.C., Sarkisian C.J., Portocarrero C.P., Sterner C.J., Notorfrancesco K.L., Cardiff R.D., Chodosh L.A. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005, 8:197-209.
67. Müller V., Stahmann N., Riethdorf S., Rau T., Zabel T., Goetz A., Jänicke F., Pantel K. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin. Cancer Res. 2005, 11:3678-3685.
68. Nieto M.A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol. 2011, 27:347-376.
69. Ocaña O.H., Córcoles R., Fabra A., Moreno-Bueno G., Acloque H., Vega S., Barrallo-Gimeno A., Cano A., Nieto M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22:709-724.
70. Oskarsson T., Acharyya S., Zhang X.H., Vanharanta S., Tavazoie S.F., Morris P.G., Downey R.J., Manova-Todorova K., Brogi E., Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 2011, 17:867-874.
71. Oskarsson T., Massagué J. Extracellular matrix players in metastatic niches. EMBO J. 2012, 31:254-256.
72. Pantel K., Brakenhoff R.H. Dissecting the metastatic cascade. Nat. Rev. Cancer 2004, 4:448-456.
73. Pantel K., Schlimok G., Kutter D., Schaller G., Genz T., Wiebecke B., Backmann R., Funke I., Riethmüller G. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 1991, 51:4712-4715.
74. Pantel K., Schlimok G., Braun S., Kutter D., Lindemann F., Schaller G., Funke I., Izbicki J.R., Riethmüller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J.Natl. Cancer Inst. 1993, 85:1419-1424.
75. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 2008, 8:329-340.
76. Pantel K., Denève E., Nocca D., Coffy A., Vendrell J.P., Maudelonde T., Riethdorf S., Alix-Panabières C. Circulating epithelial cells in patients with benign colon diseases. Clin. Chem. 2012, 58:936-940.
77. Parkinson D.R., Dracopoli N., Petty B.G., Compton C., Cristofanilli M., Deisseroth A., Hayes D.F., Kapke G., Kumar P., Lee J.Sh., et al. Considerations in the development of circulating tumor cell technology for clinical use. J.Transl. Med. 2012, 10:138.
78. Peinado H., Alečković M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., Hergueta-Redondo M., Williams C., García-Santos G., Ghajar C., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
79. Podsypanina K., Du Y.C., Jechlinger M., Beverly L.J., Hambardzumyan D., Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008, 321:1841-1844.
80. Raimondi C., Gradilone A., Naso G., Vincenzi B., Petracca A., Nicolazzo C., Palazzo A., Saltarelli R., Spremberg F., Cortesi E., Gazzaniga P. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 2011, 130:449-455.
81. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
82. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
83. Shiozawa Y., Pedersen E.A., Havens A.M., Jung Y., Mishra A., Joseph J., Kim J.K., Patel L.R., Ying C., Ziegler A.M., et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J.Clin. Invest. 2011, 121:1298-1312.
84. Siemens H., Jackstadt R., Hünten S., Kaller M., Menssen A., Götz U., Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011, 10:4256-4271.
85. Sosa M.S., Avivar-Valderas A., Bragado P., Wen H.-C., Aguirre-Ghiso J.A. ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin. Cancer Res. 2011, 17:5850-5857.
86. Spaderna S., Schmalhofer O., Wahlbuhl M., Dimmler A., Bauer K., Sultan A., Hlubek F., Jung A., Strand D., Eger A., et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 2008, 68:537-544.
87. Steeg P.S. Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program. Clin. Cancer Res. 2008, 14:3643-3645.
88. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
89. Toh B., Wang X., Keeble J., Sim W.J., Khoo K., Wong W.C., Kato M., Prevost-Blondel A., Thiery J.P., Abastado J.P. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011, 9:e1001162.
90. Tsai J.H., Donaher J.L., Murphy D.A., Chau S., Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22:725-736.
91. Tsuji T., Ibaragi S., Shima K., Hu M.G., Katsurano M., Sasaki A., Hu G.F. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res. 2008, 68:10377-10386.
92. Uhr J.W., Pantel K. Controversies in clinical cancer dormancy. Proc. Natl. Acad. Sci. USA 2011, 108:12396-12400.
93. van de Wouw A.J., Janssen-Heijnen M.L., Coebergh J.W., Hillen H.F. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur. J. Cancer 2002, 38:409-413.
94. Vega S., Morales A.V., Ocaña O.H., Valdés F., Fabregat I., Nieto M.A. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004, 18:1131-1143.
95. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., Waldvogel B., Vannier C., Darling D., zur Hausen A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11:1487-1495.
96. Xu D., Xu H., Ren Y., Liu C., Wang X., Zhang H., Lu P. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS ONE 2012, 7:e46670.
97. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
98. Yu M., Ting D.T., Stott S.L., Wittner B.S., Ozsolak F., Paul S., Ciciliano J.C., Smas M.E., Winokur D., Gilman A.J., et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012, 487:510-513.
99. Yu M., Bardia A., Wittner B.S., Stott S.L., Smas M.E., Ting D.T., Isakoff S.J., Ciciliano J.C., Wells M.N., Shah A.M., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339:580-584.
100. Zhang X.H., Wang Q., Gerald W., Hudis C.A., Norton L., Smid M., Foekens J.A., Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78.